-
The school district is self-insured, meaning it foots the bill for the health care costs of employees. As many as 3,500 employees may be affected by insulin price increases over the past 20 years.
-
Sen. Bernie Sanders’ broad statement on U.S. drug prices doesn’t paint the full picture. Studies we examined generally found that U.S. prices were 2 to 4 times those in other countries, not 10.
-
The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.
-
Drugmakers long ceased to be the only villain of the insulin price scandal. While Lilly is cutting the list price” and others may follow, will other "parties" (i.e. pharmacy benefit managers) cause this price to increase before it hits the pharmacy counter?
-
Drug pricing experts predict the move will help other initiatives to bring lower-cost insulin to market and maintain pressure on Eli Lilly to keep its prices down.
-
Lilly said it will cut the list prices for its most commonly prescribed insulin, Humalog, and for another insulin, Humulin, by 70% or more in the fourth quarter, which starts in October.
-
Twitter has been a hotbed for the insulin access movement and activism surrounding other medical conditions - helping propel concern about the prices into policy. Can it continue to win with hashtags?
-
In August, Congress approved a $35 cap on what seniors will pay for insulin, but that change came too late to add to the online tool that helps Medicare beneficiaries compare drug and medical plans.
-
A diabetes diagnosis is not always related to a person’s weight or overall health, especially for those with Type 1 diabetes, who are dependent on insulin treatment for life.
-
The U.S. House is considering a bill to give Medicare the power to negotiate lower costs for prescription drugs like insulin, a life-saving diabetes medicine that can cost families thousands of dollars a year.